sji12075-sup-0001-FigureS1.epsimage/eps4516KFigure S1. (A) Levels of Wnt5a protein expression in primary human monocytes. (B–C) Flow cytometric analyses of Mo-mDC cultures treated or not with rWnt3a or rWnt5a.
sji12075-sup-0002-FigureS2.epsimage/eps3811KFigure S2. (A) Representative dot plots of Wnt5a treated Mo-mDC cultures. (B–C) CD209 expression on CD14+/low or CD14++ expressing cells in Mo-mDC cultures. (D) CD14/CD209 dot plot of Wnt5a treated Mo cultures using GM-CSF only (and not IL-4).
sji12075-sup-0003-FigureS3.epsimage/eps6014KFigure S3. (A–E) Functional assays of cells in Mo-mDC cultures untreated or treated with rWnt3a or rWnt5a. (A–B) Pinocytosis by human Mo-mDC measured as FITC-dextran uptake. (C–D) Allogeneic mixed lymphocyte reaction (MLR) of primary human Mo-mDCs and T cells. (E) Mo-mDC secretion of IL-6 (left), IL-12 (middle), and IL-10 (right) measured by ELISA.
sji12075-sup-0004-FigureS4.epsimage/eps9178KFigure S4. (A) Representative CD14/CD209 dot plots and gates for Fig 3D. (B) Flow cytometric analyses of HLA-DR expression levels (MFI) on monocyte populations. (C) Wnt5a induced IL-6 production by MDA-MB-231 breast cancer cells. (D) Antibody control cultures for experiments in Fig. 5
sji12075-sup-0005-Figure-captions.docxWord document135K 

Please note: Wiley Blackwell is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.